Last reviewed · How we verify
Intravitreal Implant in Applicator
At a glance
| Generic name | Intravitreal Implant in Applicator |
|---|---|
| Also known as | Ozurdex |
| Sponsor | Uptown Eye Specialists |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy (PHASE3)
- Dexamethasone Implant for Retinal Detachment in Uveal Melanoma (PHASE1)
- A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina (PHASE3)
- Ozurdex in Suboptimal Diabetic Macular Edema Patients (NA)
- Intravitreal Aflibercept Injection or Early Vitrectomy for Diabetic Vitreous Hemorrhage (PHASE4)
- Effect of Dexamethasone Implant on Optic Disc
- A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration (PHASE2)
- Iluvien Registry Safety Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravitreal Implant in Applicator CI brief — competitive landscape report
- Intravitreal Implant in Applicator updates RSS · CI watch RSS
- Uptown Eye Specialists portfolio CI